Compare BioNano Genomics Inc (BNGO) vs iShares MSCI Indonesia ETF (EIDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs iShares MSCI Indonesia ETF — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while iShares MSCI Indonesia ETF trades at $12. The key difference: iShares MSCI Indonesia ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | EIDO | |
|---|---|---|
Market Cap | $13.20M | — |
Sector | Health | — |
52-Week High | $4.92 | $19.22 |
52-Week Low | $1.09 | $10.80 |
Enterprise Value | $15.81M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
EIDO trades at $11.98, up 1.1% today, but technical indicators signal a bearish trend with moving averages and RSI_6 suggesting caution. The ETF's dividend was cut by 27% in 2025, reflecting underlying pressures. Recent news highlights Indonesia's economic initiatives, including AI integration in government programs, which could boost GDP but face currency volatility from Bank Indonesia's rate hikes to defend the rupiah.
Outlook remains mixed: potential growth from Indonesia's economic policies offers opportunity, but risks from currency instability and dividend reductions weigh on investor confidence. The bearish technical setup and lack of recent fundamental data necessitate careful evaluation of emerging market exposure amid global macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →
